NOVATO, Calif., Feb. 21 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 23, at 5:00 p.m. ET (23:00 CET) to discuss fourth quarter and year-end 2005 financial results.
What: BioMarin Fourth Quarter and Year-End 2005 Earnings Call and Webcast When: Thursday, February 23, 2006 at 5:00 p.m. ET (23:00 CET) U.S. / Canada Dial-in Number: 866-825-3308 International Dial-in Number: 617-213-8062 Participant Code: 95873939 Replay Dial-in Number: 888-286-8010 Replay International Dial-in Number: 617-801-6888 Replay Code: 32640583
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for at least one week following the call.
About BioMarin
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company’s product portfolio is comprised of three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), and Orapred(R) (prednisolone sodium phosphate oral solution) for inflammatory conditions. Investigational product candidates include Phenoptin(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU). For additional information, please visit www.BMRN.com. Information on BioMarin’s website is not incorporated by reference into this press release.
NOTE: Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC. Orapred(R) is a registered trademark of Medicis Pediatrics, Inc. and is used under license.
BioMarin Pharmaceutical Inc.
CONTACT: investors, Joshua A. Grass, +1-415-506-6777, or media, SusanFerris, +1-415-506-6701, both of BioMarin Pharmaceutical Inc.
Web site: http://www.BMRN.com/
